Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
14%
Acute Myeloid Leukemia
41%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
58%
Allogeneic Transplantation
10%
Autologous Stem Cell Transplantation (auto-SCT)
16%
Autologous Transplantation
13%
Bortezomib
19%
Carfilzomib
12%
Carmustine
12%
CD34+
10%
CD34+ Cells
11%
Chemotherapy
17%
Chronic Graft-versus-host Disease (cGVHD)
22%
Complete Remission
18%
COVID-19
19%
Cyclophosphamide
17%
Daratumumab
10%
Engraftment
11%
Etoposide
14%
Event-free Survival
13%
Graft-versus-host Disease (GvHD)
12%
Granulocyte Colony-stimulating Factor (G-CSF)
33%
Hematological Malignancies
15%
Hematopoietic Cell Transplantation
24%
Hematopoietic Stem Cells
11%
High Dose
17%
High Risk
15%
High-dose Chemotherapy
15%
High-dose Therapy
15%
Lenalidomide
20%
Leukemia
14%
Melphalan
11%
Metastatic Breast Cancer
10%
Multiple Myeloma
100%
Myelodysplastic Syndrome
19%
Myeloma
14%
Natural Killer Cells
11%
NCCN Guidelines
15%
Non-Hodgkin Lymphoma
16%
Overall Response Rate
13%
Overall Survival
25%
Patients with Cancer
10%
Peripheral Blood Progenitor Cells
13%
Phase I Study
27%
Phase II Trial
10%
Plerixafor
17%
Pomalidomide
13%
Progression-free Survival
10%
Relapsed/refractory multiple Myeloma
25%
Transplantation
15%
Medicine and Dentistry
Acute Myeloid Leukemia
29%
Allogeneic Stem Cell Transplantation
6%
Allograft
8%
Amyloidosis
6%
Autotransplantation
8%
Azacitidine
7%
Bortezomib
7%
Breast Cancer
7%
Cardio-Oncology
7%
Carmustine
14%
Cell Transplantation
38%
Chemotherapy
28%
Clinical Research
5%
Comorbidity
6%
COVID-19
19%
Cyclophosphamide
11%
Cytarabine
7%
Daratumumab
7%
Decitabine
7%
Dexamethasone
14%
Diseases
20%
Drug Megadose
24%
Etoposide
13%
Event Free Survival
7%
Graft Versus Host Reaction
7%
Granulocyte Colony Stimulating Factor
14%
Hematologic Malignancy
8%
Hematopoietic Cell
51%
High Dose Chemotherapy
13%
Immunoglobulin Idiotype
6%
Infection
7%
Malignant Neoplasm
19%
Median Follow Up
7%
Melphalan
8%
Metastatic Breast Cancer
8%
Multiple Myeloma
85%
Myelodysplastic Syndrome
16%
Myeloma
13%
Non-Hodgkin Lymphoma
14%
Oncology
9%
Overall Survival
20%
Plerixafor
10%
Progenitor Cell
9%
Progression Free Survival
8%
Salvage Therapy
7%
Stem Cell
7%
Stem Cell Mobilization
8%
Stem Cell Therapy
7%
Stem Cell Transplant
11%
Whole Body Radiation
6%
Immunology and Microbiology
Acute Graft Versus Host Disease
8%
Allogeneic Stem Cell Transplantation
8%
Allograft
12%
Amyloidosis
7%
Apheresis
6%
Autotransplantation
10%
Bone Marrow Transplantation
6%
CD34
24%
CD8
5%
Cell Transplantation
51%
Chronic Graft Versus Host Disease
9%
COVID-19
16%
Cyclophosphamide
19%
Cytomegalovirus
6%
Daratumumab
7%
Dendritic Cell
7%
Dexamethasone
19%
Drug Megadose
28%
Elotuzumab
7%
Engraftment
16%
Event Free Survival
9%
Graft-Versus-Host Disease
18%
Granulocyte
5%
Granulocyte Colony-Stimulating Factor
22%
Hematopoietic Cell
70%
Hematopoietic Stem Cell Transplantation
5%
Idiotype
6%
Immunoglobulin Producing Cell
6%
Infection
7%
Infectious Disease
7%
Lenalidomide
7%
Light Chain
6%
Multiple Myeloma
53%
Myeloid
29%
Natural Killer Cell
12%
Overall Survival
21%
Plerixafor
15%
Pomalidomide
7%
Prednisone
6%
Progression Free Survival
10%
Stem Cell
22%